The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada ...
GlobalData on MSN6d
PTC Therapeutics ALS drug fails to meet endpoints as trials shut downThe announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...
Instead of feeling down, Maya and Maceo focus on what's still possible, pushing the boundaries of what the preconceived ...
Lou Gehrig’s disease, also known as ALS, has taken away some of the greatest minds and athletes. ALS and frontotemporal ...
The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...
After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for ...
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...
PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...
Philadelphia dad Eric Brunner fell into a depression after he was diagnosed with amyotrophic lateral sclerosis, the fatal disease commonly known as ALS. “Doctors are like, ‘You have 2 to 5 ...
At Lenovo Tech World ’24, global technology leader Lenovo and the Scott-Morgan Foundation (SMF), a non-profit pioneering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback